{"id":"NCT01047839","sponsor":"Valneva Austria GmbH","briefTitle":"Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO速, JESPECT速) in a Pediatric Population in Non-endemic Countries","officialTitle":"Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO速, JESPECT速) in a Pediatric Population in Non-endemic Countries. Uncontrolled, Open-label Phase 3 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2010-01-13","resultsPosted":"2014-12-19","lastUpdate":"2020-06-30"},"enrollment":100,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"IC51","otherNames":[]},{"type":"BIOLOGICAL","name":"IC51","otherNames":[]},{"type":"BIOLOGICAL","name":"IC51","otherNames":[]}],"arms":[{"label":">=2 months to <3 years","type":"EXPERIMENTAL"},{"label":">=3 to <12 years","type":"EXPERIMENTAL"},{"label":">=12 to <18 years","type":"EXPERIMENTAL"}],"summary":"The primary objective is to assess the safety profile of IC51 in a pediatric population from regions where JEV is not endemic","primaryOutcome":{"measure":"Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Day 56 After the First Vaccination","timeFrame":"until Day 56","effectByArm":[{"arm":">=2 Months to <3 Years","deltaMin":33.3,"sd":null},{"arm":">=3 to <12 Years","deltaMin":20.7,"sd":null},{"arm":">=12 to <18 Years","deltaMin":3.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":10,"countries":["United States","Australia","Denmark","Germany","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Tenderness","Muscle Pain","Injection Site Pain","Excessive Fatigue","Nasopharyngitis"]}}